AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BioGaia

AGM Information Nov 25, 2020

3013_rns_2020-11-25_be1107a5-7ad6-467d-8f64-9403da936fa3.pdf

AGM Information

Open in Viewer

Opens in native device viewer

Extraordinary General Meeting of BioGaia

The Extraordinary General Meeting of BioGaia AB (publ) 25 November 2020 resolved in accordance with the following:

  • that the number of Board members shall be eight without deputies
  • to elect Niklas Ringby as new Board member
  • that no remuneration shall be paid to Niklas Ringby
  • to approve the Board's resolution from 30 October 2020 to increase the company's share capital with not more than SEK 1,126,354 through issue of not more than 1,126,354 new class B shares.

For more information on the new Board member, refer to the notice to the meeting. For further details and information on background to and reasons for the new share issue, refer to the company's press release 30 October 2020.

For additional information please contact

Isabelle Ducellier, CEO, telephone: +46 8 555 293 00

Latest press releases from BioGaia

03.11.2020 Nominating Committee ahead of the BioGaia AGM 6 May 2021.
02.11.2020 Notice to attend the Extraordinary General Meeting of BioGaia AB (publ)
30.10.2020 BioGaia has carried out a directed issue of 2.86 million class B shares, raising proceeds to SEK 1.1
billion

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.